TABLE 4.
The 40 cytokines/chemokines analyzed in this study
| Cytokine/chemokinea |
|---|
| 6Ckine/CCL21 |
| BCA-1/CXCL13 |
| CTACK/CCL27 |
| ENA-78/CXCL5 |
| Eotaxin/CCL11 |
| Eotaxin-2/CCL24 |
| Eotaxin-3/CCL26 |
| Fractalkine/CX3CL1 |
| GCP-2/CXCL6 |
| GM-CSF |
| Gro-α/CXCL1 |
| Gro-β/CXCL2 |
| I-309/CCL1 |
| IFN-γ |
| IL-1β |
| IL-2 |
| IL-4 |
| IL-6 |
| IL-8/CXCL8 |
| IL-10 |
| IL-16 |
| IP-10/CXCL10 |
| I-TAC/CXCL11 |
| MCP-1/CCL2 |
| MCP-2/CCL8 |
| MCP-3/CCL7 |
| MCP-4/CCL13 |
| MDC/CCL22 |
| MIF |
| MIG/CXCL9 |
| MIP-1α/CCL3 |
| MIP-1δ/CCL15 |
| MIP-3α/CCL20 |
| MIP-3β/CCL19 |
| MPIF-1/CCL23 |
| SCYB16/CXCL16 |
| SDF-1α+β/CXCL12 |
| TARC/CCL17 |
| TECK/CCL25 |
| TNF-α |
BCA-1, B-cell-attracting chemokine 1; CCL21, chemokine (C-C motif) ligand 21; CTACK, cutaneous T-cell-attracting chemokine; CXCL13, chemokine (C-X-C motif) ligand 13; CX3CL1, chemokine (C-X3-C motif) ligand 1; ENA-78, epithelial cell-derived neutrophil-activating peptide 78; GCP-2, granulocyte chemotactic protein 2; GM-CSF, granulocyte-macrophage colony-stimulating factor; Gro-α, growth-related oncogene α; IFN-γ, gamma interferon; IL-1β, interleukin-1β; IP-10, gamma interferon-induced protein 10; I-TAC, interferon-inducible T-cell alpha chemoattractant; MCP-1, monocyte chemotactic and activating factor 1; MDC, macrophage-derived chemokine; MIF, macrophage migration inhibitory factor; MIG, monokine induced by gamma interferon; MIP-1α, macrophage inflammatory protein 1α; MPIF-1, myeloid progenitor inhibitory factor 1; SCYB16, small inducible cytokine B 16; SDF-1α+β, stromal cell-derived factor 1α and -β; TARC, thymus- and activation-regulated chemokine; TECK, thymus-expressed chemokine; TNF-α, tumor necrosis factor alpha.